Osteoporosis market to reach $17.9b by 2033

One growth driver is the increasing adoption of expensive anabolic therapies.

The osteoporosis market is forecasted to grow from $10.5b in 2023 to $17.9b by 2033 at a compound annual growth rate (CAGR) of 5.4% across seven major markets namely, US, France, Germany, Italy, Spain, the UK and Japan
said GlobalData.

The sector’s expansion is attributed to the rising adoption of expensive anabolic therapies and a growing patient population due to ageing demographics.

Sulayman Patel, MSci, Pharma Analyst at GlobalData, noted that anabolic therapies, which stimulate bone formation, are crucial for treating osteoporosis. 

“Despite their higher cost over traditional bisphosphonates, their effectiveness in enhancing bone density justifies their increasing adoption,” Patel said.

Recent advances in machine learning are also impacting the market by introducing new tools designed to improve the precision of osteoporosis and fracture detection through the analysis of large patient datasets to identify risk factors.

However, barriers, such as the loss of patent protection for key drugs, may impede the market’s expansion.

In addition, low compliance with osteoporosis drugs due to disruptive therapy regimens and adverse side effects remains a concern for further growth.